Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children

NCT03375502 is registered in ClinicalTrials.gov with Green Cross Corporation as lead sponsor.

NCT NCT03375502
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03375502 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III, Single-blind(Stage 1), Double-blinded(Stage 2), Randomized, Active-controlled, Dose-escalation(Stage 1), Non-inferiority(Stage 2) Study to Evaluate Immunogenicity and Safety of MG1111 in Healthy Children
Lead sponsor
Green Cross Corporation
Phase
Phase 2/3
Overall status
Completed
Start date
November 26, 2016
Completion date
July 31, 2019
Enrollment
814 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy children